{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:00:17Z","timestamp":1791306017341,"version":"4.3.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,27]],"date-time":"2017-02-27T00:00:00Z","timestamp":1488153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006388","name":"Geneva University Hospitals","doi-asserted-by":"crossref","award":["115618"],"award-info":[{"award-number":["115618"]}],"id":[{"id":"10.13039\/501100006388","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Combatting Bacterial Resistance in Europe (COMBACTE-Net)","award":["115523"],"award-info":[{"award-number":["115523"]}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","award":["WS1980748"],"award-info":[{"award-number":["WS1980748"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007534","name":"B. Braun","doi-asserted-by":"crossref","award":["HUG CER 10-085"],"award-info":[{"award-number":["HUG CER 10-085"]}],"id":[{"id":"10.13039\/100007534","id-type":"DOI","asserted-by":"crossref"}]},{"name":"GSK"},{"name":"Janssen"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bayer"},{"name":"DaVolterra"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.cmi.2017.02.011","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T09:45:48Z","timestamp":1487670348000},"page":"659-666","source":"Crossref","is-referenced-by-count":8,"title":["Comparing the cost-effectiveness of linezolid to trimethoprim\/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus infection: a healthcare system perspective"],"prefix":"10.1016","volume":"23","author":[{"given":"E.","family":"von Dach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Macedo-Vinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Olearo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Harbarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2017.02.011_bib1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1469-0691.2009.02701.x","article-title":"Management of methicillin-resistant Staphylococcus aureus infections","volume":"15","author":"Garau","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2017.02.011_bib2","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1086\/424506","article-title":"A\u00a0randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection","volume":"39","author":"Schrenzel","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.02.011_bib3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/jac\/dkh048","article-title":"Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study","volume":"53","author":"Cepeda","year":"2004","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2017.02.011_bib4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/jac\/dkl017","article-title":"Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK","volume":"57","author":"Gemmell","year":"2006","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2017.02.011_bib5","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/jac\/dkl283","article-title":"Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus","volume":"58","author":"Kaka","year":"2006","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2017.02.011_bib6","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/jac\/dku352","article-title":"Randomized non-inferiority trial to compare trimethoprim\/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection","volume":"70","author":"Harbarth","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2017.02.011_bib7","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00264-013-1856-y","article-title":"The safety and efficacy of high-dose daptomycin combined with rifampicin for the treatment of Gram-positive osteoarticular infections","volume":"37","author":"Jugun","year":"2013","journal-title":"Int Orthop"},{"key":"10.1016\/j.cmi.2017.02.011_bib8","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/heapol\/czl018","article-title":"Calculating QALYs, comparing QALY and DALY calculations","volume":"21","author":"Sassi","year":"2006","journal-title":"Health Policy Plan"},{"key":"10.1016\/j.cmi.2017.02.011_bib9","series-title":"EQ-5D value sets: inventory, comparative review, and user guide","author":"Szende","year":"2007"},{"key":"10.1016\/j.cmi.2017.02.011_bib10","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1590\/S0004-282X2011000300010","article-title":"Validation of the EuroQol quality of life questionnaire on stroke victims","volume":"69","author":"Pinto","year":"2011","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.cmi.2017.02.011_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0272989X8500500205","article-title":"Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach","volume":"5","author":"Doubilet","year":"1985","journal-title":"Med Decis Making"},{"key":"10.1016\/j.cmi.2017.02.011_bib12","series-title":"Influence des g\u00e9n\u00e9riques sur le march\u00e9 des m\u00e9dicaments","author":"Roth","year":"2013"},{"key":"10.1016\/j.cmi.2017.02.011_bib13","first-page":"1","article-title":"A\u00a0cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK","author":"Muduma","year":"2016","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.cmi.2017.02.011_bib14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/bjd.14799","article-title":"Major psychological complications and decreased health-related quality of life among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"175","author":"Dodiuk-Gad","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cmi.2017.02.011_bib15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1524-4733.2008.00401.x","article-title":"An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard","volume":"12","author":"Lee","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.cmi.2017.02.011_bib16","series-title":"Current topics in microbiology and immunology","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/82_2016_3","article-title":"Worldwide epidemiology and antibiotic resistance of Staphylococcus aureus","author":"Monaco","year":"2016"},{"key":"10.1016\/j.cmi.2017.02.011_bib17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.7326\/0003-4819-144-5-200603070-00005","article-title":"Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections","volume":"144","author":"King","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2017.02.011_bib18","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S0140-6736(06)68853-3","article-title":"Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat","volume":"368","author":"Grundmann","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2017.02.011_bib19","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jval.2015.04.007","article-title":"Linezolid versus vancomycin in the empiric treatment of nosocomial pneumonia: a cost-utility analysis incorporating results from the ZEPHyR Trial","volume":"18","author":"Collins","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.cmi.2017.02.011_bib20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jval.2010.12.006","article-title":"Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis","volume":"14","author":"Bounthavong","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.cmi.2017.02.011_bib21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.medmal.2009.01.005","article-title":"Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France","volume":"39","author":"De Cock","year":"2009","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.cmi.2017.02.011_bib22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10198-008-0104-7","article-title":"Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany","volume":"10","author":"Schurmann","year":"2009","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.cmi.2017.02.011_bib23","first-page":"53","article-title":"Economic evaluation among Chinese patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus and treated with linezolid or vancomycin: a secondary, post-hoc analysis based on a Phase 4 clinical trial study","volume":"19","author":"Wan","year":"2016","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.cmi.2017.02.011_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2014.06.029","article-title":"Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter randomized clinical trial of vancomycin and linezolid","volume":"36","author":"Niederman","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.cmi.2017.02.011_bib25","doi-asserted-by":"crossref","first-page":"R157","DOI":"10.1186\/cc13996","article-title":"Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus","volume":"18","author":"Patel","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2017.02.011_bib26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1185\/030079906X162700","article-title":"Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections","volume":"23","author":"Patanwala","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cmi.2017.02.011_bib27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1586\/14737167.8.2.165","article-title":"Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold","volume":"8","author":"Grosse","year":"2008","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.cmi.2017.02.011_bib28","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A\u00a0systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.cmi.2017.02.011_bib29","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.02.011_bib30","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1128\/JCM.01061-11","article-title":"Molecular and epidemiological evaluation of strain replacement in patients previously harboring gentamicin-resistant MRSA","volume":"49","author":"De Angelis","year":"2011","journal-title":"J\u00a0Clin Microbiol"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X1730099X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X1730099X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T16:13:10Z","timestamp":1589731990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X1730099X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S1198743X1730099X"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2017.02.011","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}